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Background:  Type B insulin resistance syndrome is a manifestation of autoantibodies to the insulin receptor that results in se-
vere hyperglycemia and acanthosis nigricans. However, the mechanisms by which these autoantibodies induce hypoglycemia are 
largely unknown. In this paper, we report the case of patient with type B insulin resistance syndrome who presented with fre-
quent severe fasting hypoglycemia and acanthosis nigricans. 
Methods:  To evaluate the mechanism of hypoglycemia, we measured the inhibition of insulin binding to erythrocytes and IM9 
lymphocytes in a sample of the patient’s dialyzed serum before and after immunosuppressive therapy.
Results:  In the patient’s pre-treatment serum IgG, the binding of 
125I-insulin to erythrocytes was markedly inhibited in a dose-
dependent manner until the cold insulin level reached 10
-9 mol/L. We also observed dose-dependent inhibition of insulin bind-
ing to IM9 lymphocytes, which reached approximately 82% inhibition and persisted even when diluted 1:20. After treatment 
with glucocorticoids, insulin-erythrocyte binding activity returned to between 70% and 80% of normal, while the inhibition of 
insulin-lymphocyte binding was reduced by 17%.
Conclusion:  We treated a patient with type B insulin resistance syndrome showing recurrent fasting hypoglycemia with steroids 
and azathioprine. We characterized the patient’s insulin receptor antibodies by measuring the inhibition of insulin binding.
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INTRODUCTION
Autoimmune hypoglycemia is a very rare disease caused by 
autoantibodies to the insulin receptor or to insulin itself [1]. 
Insulin antibody-mediated hypoglycemia is more common in 
autoimmune hypoglycemia [2]. Type B insulin resistance syn-
drome is a rare disorder characterized by severe hyperglyce-
mia and acanthosis nigricans in which autoantibodies to the 
insulin receptor are present in serum [3]. On review of the lit-
erature, there are few cases of spontaneous fasting hypoglyce-
mia reported, which is difficult to distinguish from other causes 
of hypoglycemia such as insulinoma [4,5]. Insulin receptor 
antibodies may cause hyperglycemia and/or hypoglycemia, 
and have been studied in vitro [3,6]. However, the rarity of in-
sulin receptor antibody-mediated hypoglycemia has prevent-
ed extensive research into its mechanism.
  Recently, we experienced a case of male patient with fre-
quent, severe fasting hypoglycemia and acanthosis nigricans. 
He had no significant medical history and no history of auto-
immune disease. Laboratory evaluation revealed the presence 
of insulin receptor antibodies in his serum. We treated him 
with glucocorticoids and azathioprine. In order to evaluate the 
mechanism of insulin receptor antibody-induced hypoglyce-
mia, we analyzed the behavior of antibodies in his serum.
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METHODS
Case history
A 35-year-old man presented with severe, episodic fasting hy-
poglycemia for the past several months as evidenced by sweat-
ing, anxiety, and episodes of unconsciousness. He had gained 
12 kg over the past 6 months. His medical history was unre-
markable. Physical exam revealed extensive acanthosis nigri-
cans on his posterior neck, axillary, and inguinal areas (Fig. 1). 
We confirmed the diagnosis of fasting hypoglycemia with an 
attempted 72-hour fasting test (Fig. 2). At 4 hour after fasting, 
he complained of hypoglycemic symptoms and his blood glu-
cose level was 44 mg/dL, plasma insulin level was 19.8 μU/mL, 
plasma proinsulin level was 14.11 pmol/L, and C-peptide was 
undetectable. The test was terminated after 9 hours due to se-
vere hypoglycemia: his blood glucose level was 38 mg/dL. De-
spite worsening hypoglycemia, his insulin level slowly decreased 
and his C-peptide level remained undetectable. We performed 
computed tomography to exclude the possibility of insulino-
ma and found no evidence of a pancreatic mass. Percutaneous 
transhepatic portal and splenic venous sampling did not show 
abnormally elevated insulin or C-peptide levels. The patient 
had a normal adrenal response to a rapid ACTH stimulation 
test and normal thyroid function tests. We performed a 75 g 
oral glucose tolerance test to evaluate his insulin secretory ca-
pacity. Glucose excursion was normal, but insulin and C-pep-
tide secretion increased in a delayed pattern and remained 
consistently elevated despite a normal glucose level (Fig. 3A).
  We analyzed the patient’s serum for autoantibodies to eval-
uate for associated autoimmune diseases. Serologic exam was 
unremarkable: tests were negative for rheumatoid factor, anti-
nuclear antibodies, anti-ds DNA antibodies, and anti-thyroid 
antibodies. Serum immunoglobulin levels (G, A, M, and E) 
were also within normal limits. Although the level of insulin 
antibodies was 6.7% (reference range, 0-7%), the insulin re-
ceptor antibody was positive by radioreceptor assay.
  We obtained written informed consent from the patient and 
the study protocol was approved by the Institutional Review 
Fig. 2.  Initial 24-hour glucose profile using a continuous glu-
cose monitoring system during a 72-hour fasting test.
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Fig. 3.  Pre- and post-treatment serum levels of insulin and C-
peptide after 75 g oral glucose tolerance test. (A) On admis-
sion. (B) Sixteen-month follow-up.
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Fig. 1.  Thickened, hyperpigmented skin lesions (acanthosis 
nigricans) were observed on the posterior neck, axillae and 
groin.
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Methods
Preparation of the serum IgG fraction 
We dialyzed the patient’s serum through a membrane that ex-
cluded molecules less than 50,000 MW. The complements in 
serum were heat-inactivated at 56°C for 30 minutes and then 
run the dialyzed serum through a protein A affinity column 
(Hi-Trap affinity column). After washing with 10 mL PBS, the 
bound IgG was eluted with 3 mL of 100 mM sodium citrate 
(pH 3.5). We dialyzed the samples again and determined im-
munoglobulin concentrations.
Insulin binding of erythrocytes
Insulin binding was determined as previously reported [7,8] 
on freshly isolated erythrocytes drawn under fasting condi-
tions and purified on cellulose columns. Results are expressed 
as the percent specific binding for an erythrocyte suspension 
containing 4×10
6 RBC/μL.
Binding studies
To determine the insulin-erythrocyte binding activity, we per-
formed binding studies using a radioreceptor assay.
  We determined the extent of erythrocyte binding to 
125I-la-
beled insulin by incubating a 400-μL cell suspension (1.75×
10
6 cells in buffer G), 20 pg of 
125I-labeled insulin in 25 μL of 
buffer, and various amounts of unlabeled insulin (0 to 0.5×10
5 
ng) in a total volume of 0.5 mL. After incubation at 15°C for 3 
hours, we placed 200 μL aliquots of the suspension into pre-
chilled microfuge tubes containing 200 μL buffer G and 200 
μL dibutyl phthalate and centrifuged them for 10 minutes in a 
Beckman Microfuge B (Beckman Instruments Inc., Fullerton, 
CA, USA). We determined the radioactivity of the cells by gam-
ma counter.
Inhibition of insulin binding of human IM9 lymphocytes 
We also investigated the insulin receptor binding activity of 
human lymphocytes, which carry insulin receptors that reflect 
insulin sensitivity. We pre-incubated 7.5×10
6 IM9 cells with 
serial dilutions of patient serum or control serum at 37°C for 
30 minutes in 800 μL assay buffer (100 mM HEPES, 120 mM 
NaCl, 1.2 mM MgSO4, 2.4 mM KCl, 1 mM glucose, 1 mM 
EDTA, 1% bovine serum albumin, pH 7.8). Cells were washed 
with phosphate-buffered saline and incubated with 
125I-insulin 
in a final volume of 500 μL assay buffer at 15°C. At the end of 
the 90-minute incubation period, we centrifuged cells and 
separated cell-associated radioactivity from free 
125I-insulin by 
adding 200 μL dibutylphthalate [3]. 
RESULTS
Clinical course
Following the laboratory investigation, we diagnosed the pa-
tient with autoimmune hypoglycemia caused by insulin recep-
tor antibodies and treated him with two courses of plasma-
pheresis. The patient’s symptoms did not improve (Fig. 4A), so 
Fig. 4.  Post-treatment 24-hour glucose profile using a continuous glucose monitoring system. (A) After plasmapheresis. (B) Af-
ter steroid treatment.
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we added immunosuppressive agents. We first treated the pa-
tient with prednisolone 80 mg/day, which we eventually ta-
pered to 20 mg/day 11 months after admission. The patient ex-
perienced no hypoglycemia attack during prednisolone treat-
ment (Fig. 4B), although he suffered from mild recurrent hy-
poglycemia and skin inflammation at doses less than 20 mg/
day. As a steroid-sparing agent, we added the azathioprine 100 
mg/day to a physiologic prednisolone dose of 7.5 mg/day. The 
patient experienced no hypoglycemia during the 6 months of 
azathioprine treatment, and his skin inflammation and acan-
thosis nigricans improved. 
  We performed a 75 g glucose tolerance test 16 months after 
admission to measure glucose, insulin, and C-peptide levels 
(Fig. 3B). Compared to the initial test, the serum glucose level 
had increased to over 200 mg/dL; both insulin and C-peptide 
levels had also increased. We also found that the increment of 
insulin level during the glucose excursion was faster than that 
of initial test. Currently, our patient is maintained on azathio-
prine 100 mg/day, and has not experienced any episodes of 
hypoglycemia.
Analysis of insulin binding of erythrocytes
We compared the insulin receptor binding activity of our pa-
tient’s pre-treatment serum, post-treatment serum, and nor-
mal human serum by adding cold insulin (10
-12 to 10
-6 mol/L) 
to normal human erythrocytes. In the case of the patient’s pre-
treatment serum, insulin receptor binding activity was inhib-
ited in a dose-dependent manner until the cold insulin level 
reached 10
-9 mol/L. This result specifically suggests that the 
patient’s serum contained insulin receptor antibodies. After 
treatment, binding activity recovered to 70% to 80% of normal 
(Fig. 5).
Analysis of insulin binding of IM9 lymphocytes
The ability of the patient’s serum to inhibit the binding of 
125I-
insulin to IM9 lymphocytes is shown in Fig. 6. We measured 
insulin receptor binding activity by diluting IgG purified from 
normal human serum, the patient’s pre-treatment serum, and 
the patient’s post-treatment serum to 1:20, 1:40, 1:160, 1:320, 
and 1:640 each in IM9 cell lines. The insulin binding activity 
of the patient’s pre-treatment IgG was reduced in a dose-de-
pendent manner compared to normal IgG. Most dramatically, 
the 1:20 dilution was 82% inhibited compared to normal IgG. 
Notably, this inhibitory effect was reduced to 17% after treat-
ment (Fig. 6).
DISCUSSION
Insulin resistance syndrome can be classified into type A, in 
which insulin receptors are absent, and type B, in which insu-
lin receptor autoantibodies are present in serum [1]. First re-
ported by Kahn et al. [9] in 1976, type B insulin resistance syn-
drome occurs most often in adult women who show other 
symptoms of autoimmune disease. It can be diagnosed by de-
tection of insulin receptor antibodies [10,11]. 
  Clinical symptoms can include hyperglycemia, hypoglyce-
mia, hyperinsulinemia, severe insulin resistance, and acantho-
Fig. 6.  Effect of serum IgG on insulin binding of IM9 lym-
phocytes.
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Fig. 5.  Effect of serum IgG on insulin binding of erythrocytes.
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sis nigricans [1,9,12,13]. While hyperglycemia is a more com-
mon symptom, hypoglycemia can occasionally cause serious 
problems [5,14]. In this paper, we describe a patient with re-
current symptomatic fasting hypoglycemia. This phenomenon 
appears to be caused by the binding of autoantibodies to insu-
lin receptors, which inhibits the degradation of insulin and re-
sults in hyperinsulinemia followed by subsequent hypoglyce-
mia [5]. In some cases, hyperglycemia and hypoglycemia may 
occur alternately in one patient [15], which suggests there are 
at least two subtypes of insulin receptor antibodies [14,16]. 
  The IgG insulin receptor antibody binds the insulin recep-
tor and can have two different effects. Its function can be either 
inhibitory (by inhibiting insulin binding) or stimulatory (with 
an insulin-like action), both resulting in hypoglycemia [5,14, 
15,17]. These different interactions may be explained by quan-
titative differences in antibody titers. At low titers, the autoan-
tibody appears to act as a partial agonist and result in hypogly-
cemia, while at high titers it appears to down-regulate the re-
ceptor’s response to insulin and result in hyperglycemia [14,18]. 
In our patient, we measured insulin receptor antibodies by 
quantifying the inhibition of insulin binding to both erythro-
cytes and IM9 lymphocytes. However, this method is unable 
to determine the type of activation caused by autoantibody 
binding. Therefore, further study is needed to elucidate the 
mechanism of post-receptor signaling. 
  In our patient, we observed significant inhibition of insulin 
binding to erythrocytes and IM9 lymphocytes in a dose-de-
pendent manner, which did not improve after plasmapheresis. 
Clinically, the patient’s symptoms of hypoglycemia and glucose 
tolerance improved after treatment with prednisolone and 
azathioprine. We found that insulin binding to erythrocytes 
gradually normalized to 70% to 80% of normal after immuno-
suppressive treatment. Furthermore, we found that the patient’s 
dialyzed post-treatment serum inhibited 
125I-binding to IM9 
lymphocytes by only 17%. 
  Yamasaki et al. [19] studied a patient with systemic lupus 
erythematosus and type B insulin resistance who showed the 
rapid disappearance of insulin receptor autoantibodies from 
circulation according to the treatment. They determined the 
biological and clinical relevance of the patient’s insulin recep-
tor antibodies by analyzing the inhibition of insulin binding to 
IM9 lymphocytes, the uptake of 2-deoxyglucose in CHO cells, 
and by phosphotyrosine immunoblotting of the insulin recep-
tor. After immunosuppressive treatment, they found attenua-
tion of the insulin binding inhibition present in the patient’s 
serum in parallel with the normalization of the patient’s insu-
lin sensitivity. However, in this report the stimulatory activities 
that promote 2-deoxyglucose uptake and insulin receptor phos-
phorylation were discordant with the occurrence of fasting 
hypoglycemia. Thus, this study implicated other pathogenic 
mechanisms in the development of fasting hypoglycemia, in 
addition to the insulin-like action of insulin receptor antibod-
ies.
  Our study proved that insulin binding activity was improved 
after treatment. If our study was further investigated about the 
post-receptor signaling after autoantibodies were bound to re-
ceptors, the mechanism of fasting hypoglycemia was expected 
to be clearly established.
  Immunosuppressants can be used to treat type B insulin re-
sistance. However, the treatment results have generally been 
unsatisfactory. In our case, the patient’s symptoms did not im-
prove after plasmapheresis, leading us to use a combination of 
steroids and azathioprine, which resulted in clinical improve-
ment. Arioglu et al. [20] reviewed the long-term clinical course 
of type B insulin resistance syndrome in 24 patients who were 
followed for up to 28 years. Although they found that the most 
effective short-term therapy was high-dose steroids, it remains 
unclear whether patients presenting with hypoglycemia would 
benefit from long-term steroid treatment. They also reported 
that immunomodulation therapy may not influence either the 
onset of remission or the long-term course of the disease. Nev-
ertheless, immunosuppressive therapy may be considered in 
patients presenting with severe symptoms who do not sponta-
neously remit.
  Recently, in 2010, Malek et al. [21] reported a novel approach 
to reduce the load of insulin receptor antibodies. They treated 
7 patients with type B insulin resistance syndrome with a new 
therapeutic protocol consisting of rituximab and cyclophos-
phamide combined with pulsed corticosteroids. All 7 patients 
achieved remission, defined as improved hyperglycemia, dis-
continuation of insulin therapy, and resolution of hyperan-
drogenism. This new therapeutic approach is promising in the 
treatment of both type B insulin resistance as well as other au-
toantibody receptor diseases.
REFERENCES
1. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulin-like 
growth factor receptors: proposed mechanism for acanthosis 
nigricans. J Invest Dermatol 1992;98(6 Suppl):82S-5S.Autoimmune hypoglycemia and insulin receptor antibodies
85 Diabetes Metab J 2011;35:80-85 http://e-dmj.org
2. Hirata Y, Uchigata Y. Insulin autoimmune syndrome in Japan. 
Diabetes Res Clin Pract 1994;24 Suppl:S153-7.
3. Flier JS, Kahn CR, Roth J, Bar RS. Antibodies that impair insu-
lin receptor binding in an unusual diabetic syndrome with se-
vere insulin resistance. Science 1975;190:63-5.
4. Braund WJ, Naylor BA, Williamson DH, Buley ID, Clark A, 
Chapel HM, Turner RC. Autoimmunity to insulin receptor 
and hypoglycaemia in patient with Hodgkin’s disease. Lancet 
1987;1:237-40.
5. Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, 
Dons RF, Ryan J, Roddam RF, Rupe CE, Gorden P. Hypoglyce-
mia associated with antibodies to the insulin receptor. N Engl J 
Med 1982;307:1422-6.
6. Rodriguez O, Collier E, Arakaki R, Gorden P. Characterization 
of purified autoantibodies to the insulin receptor from six pa-
tients with type B insulin resistance. Metabolism 1992;41:325-
31.
7. Dozio N, Micossi P, Galimberti G, Sartori S, Pozza G, Dosio F, 
Savi A, Gerundini PG, Fazio F, Chiumello G, et al. In vivo dem-
onstration of insulin-receptor defect with 123I-labeled insulin 
and scintigraphic scanning in severe insulin resistance. Diabe-
tes Care 1992;15:651-6.
8. Gambhir KK, Archer JA, Carter L. Insulin radioreceptor assay 
for human erythrocytes. Clin Chem 1977;23:1590-5.
9. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, 
Roth J. The syndromes of insulin resistance and acanthosis ni-
gricans. Insulin-receptor disorders in man. N Engl J Med 1976; 
294:739-45.
10. Flier JS, Eastman RC, Minaker KL, Matteson D, Rowe JW. Ac-
anthosis nigricans in obese women with hyperandrogenism. 
Characterization of an insulin-resistant state distinct from the 
type A and B syndromes. Diabetes 1985;34:101-7.
11. Taylor SI, Dons RF, Hernandez E, Roth J, Gorden P. Insulin re-
sistance associated with androgen excess in women with auto-
antibodies to the insulin receptor. Ann Intern Med 1982;97: 
851-5.
12. Accili D, Barbetti F, Cama A, Kadowaki H, Kadowaki T, Imano 
E, Levy-Toledano R, Taylor SI. Mutations in the insulin recep-
tor gene in patients with genetic syndromes of insulin resistance 
and acanthosis nigricans. J Invest Dermatol 1992;98(6 Suppl): 
77S-81S.
13. Cama A, de la Luz Sierra M, Ottini L, Kadowaki T, Gorden P, 
Imperato-McGinley J, Taylor SI. A mutation in the tyrosine ki-
nase domain of the insulin receptor associated with insulin re-
sistance in an obese woman. J Clin Endocrinol Metab 1991;73: 
894-901.
14. De Pirro R, Roth RA, Rossetti L, Goldfine ID. Characteriza-
tion of the serum from a patient with insulin resistance and 
hypoglycemia. Evidence for multiple populations of insulin 
receptor antibodies with different receptor binding and insu-
lin-mimicking activities. Diabetes 1984;33:301-4.
15. Dons RF, Havlik R, Taylor SI, Baird KL, Chernick SS, Gorden P. 
Clinical disorders associated with autoantibodies to the insulin 
receptor. Simulation by passive transfer of immunoglobulins to 
rats. J Clin Invest 1983;72:1072-80.
16. Tsushima T, Omori Y, Murakami H, Hirata Y, Shizume K. 
Demonstration of heterogeneity of autoantibodies to insulin 
receptors in type B insulin resistance by isoelectric focusing. 
Diabetes 1989;38:1090-6.
17. Pedersen O, Hjollund E, Beck-Nielsen H, Kromann H. Diabe-
tes mellitus caused by insulin-receptor blockade and impaired 
sensitivity to insulin. N Engl J Med 1981;304:1085-8.
18. Di Paolo S, Giorgino R. Insulin resistance and hypoglycemia 
in a patient with systemic lupus erythematosus: description of 
antiinsulin receptor antibodies that enhance insulin binding 
and inhibit insulin action. J Clin Endocrinol Metab 1991;73: 
650-7.
19. Yamasaki H, Yamaguchi Y, Fujita N, Kato C, Kuwahara H, 
Yamauchi MD, Yamakawa K, Abe T, Ozaki M, Sera Y, Uotani 
S, Kawasaki E, Takino H, Eguchi K. Anti-insulin receptor au-
toantibodies in a patient with type B insulin resistance and 
fasting hypoglycemia. Acta Diabetol 2000;37:189-96.
20. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. 
Clinical course of the syndrome of autoantibodies to the insu-
lin receptor (type B insulin resistance): a 28-year perspective. 
Medicine (Baltimore) 2002;81:87-100.
21. Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos 
MA, Semple RK, Balow JE, Gorden P. Treatment of type B in-
sulin resistance: a novel approach to reduce insulin receptor 
autoantibodies. J Clin Endocrinol Metab 2010;95:3641-7.